{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:58:40Z","timestamp":1754153920478,"version":"3.41.2"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.transproceed.2025.05.018","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:56:37Z","timestamp":1751010997000},"page":"1133-1142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytomegalovirus Infection Risk Factors in Allogeneic Hematopoietic Stem Cell Transplantation Can Defibrotide Be a Risk Factor?"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6950-6013","authenticated-orcid":false,"given":"Lecturer Zeynep Bur\u00e7in","family":"Y\u0131lmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-1182","authenticated-orcid":false,"given":"Funda","family":"Memi\u015fo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-7387","authenticated-orcid":false,"given":"Emine","family":"Hidayet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-0816","authenticated-orcid":false,"given":"\u0130rfan","family":"Kuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3285-417X","authenticated-orcid":false,"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8605-8497","authenticated-orcid":false,"given":"Emin","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3312-8476","authenticated-orcid":false,"given":"\u0130lhami","family":"Berber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.transproceed.2025.05.018_bib0001","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13096","article-title":"Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia","volume":"21","author":"Lin","year":"2019","journal-title":"Transplant Infect Dis"},{"key":"10.1016\/j.transproceed.2025.05.018_bib0002","unstructured":"CIBMTR Summary Slides & Reports https:\/\/cibmtr.org\/CIBMTR\/Resources\/Summary-Slides-Reports [accessed March 5, 2024]."},{"issue":"7","key":"10.1016\/j.transproceed.2025.05.018_bib0003","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.transproceed.2025.05.018_bib0004","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the american society for transplantation and cellular therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.transproceed.2025.05.018_bib0005","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41409-020-01178-6","article-title":"Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study","volume":"56","author":"Beauvais","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2025.05.018_bib0006","first-page":"292","article-title":"Efficacy of cytomegalovirus specific immunoglobulins (cmv-ig) in reducing cmv reactivation in paediatric haematopoietic stem cell transplant","volume":"57","author":"Geurten","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.transproceed.2025.05.018_bib0007","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1002\/jmv.25895","article-title":"Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation","volume":"92","author":"Peffault De Latour","year":"2020","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.transproceed.2025.05.018_bib0008","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2019.229252","article-title":"Standardized monitoring of cytomegalovirusspecific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation","volume":"106","author":"Wagner-Drouet","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.transproceed.2025.05.018_bib0009","article-title":"Slaying the \"Troll of Transplantation\"-new frontiers in cytomegalovirus management. A report from the CMV International Symposium 2023","volume":"9","author":"Kotton","year":"2023","journal-title":"Transpl Infect Dis."},{"year":"2019","series-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","key":"10.1016\/j.transproceed.2025.05.018_bib0010"},{"issue":"2","key":"10.1016\/j.transproceed.2025.05.018_bib0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.transproceed.2025.05.018_bib0012","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40261-022-01140-y","article-title":"A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"42","author":"Corbacioglu","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"8","key":"10.1016\/j.transproceed.2025.05.018_bib0013","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bmt.2009.254","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective","volume":"44","author":"Tomblyn","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.transproceed.2025.05.018_bib0014","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/bloodadvances.2017008375","article-title":"The use of defibrotide in blood and marrow transplantation","volume":"2","author":"Richardson","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.transproceed.2025.05.018_bib0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/MEG.0000000000001802","article-title":"Hepatic veno-occlusive disease development in the hematopoietic stem cell transplantation patients: incidence and associated risk factors, a meta-analysis","volume":"33","author":"Xia","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.transproceed.2025.05.018_bib0016","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtct.2023.07.023","article-title":"Role of defibrotide in the prevention of murine model graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"29","author":"Palaniyandi","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.transproceed.2025.05.018_bib0017","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/10600280211068177","article-title":"Impact of defibrotide in the prevention of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation","volume":"56","author":"Tilmont","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.transproceed.2025.05.018_bib0018","first-page":"1","article-title":"Cytomegalovirus reactivation in hematopoietic stem cell transplantation managed by preemptive treatment with lower dose Valganciclovir","volume":"4","author":"Sahin","year":"2019","journal-title":"Int J Hematol Blo Dis"},{"key":"10.1016\/j.transproceed.2025.05.018_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.828094","article-title":"Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept","volume":"13","author":"Meesters-Ensing","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.transproceed.2025.05.018_bib0020","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/tid.12398","article-title":"Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation","volume":"17","author":"Cohen","year":"2015","journal-title":"Transplant Infect"},{"issue":"12","key":"10.1016\/j.transproceed.2025.05.018_bib0021","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/bmt.2014.204","article-title":"High incidence of CMV infection in adult T-cell leukemia\/lymphoma patients after allogeneic hematopoietic stem cell transplantation","volume":"49","author":"Nakano","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.transproceed.2025.05.018_bib0022","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2006.11.024","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan","volume":"13","author":"Oran","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.transproceed.2025.05.018_bib0023","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/phar.2433","article-title":"Incidence of viral and fungal complications after utilization of alternative donor sources in hematopoietic cell transplantation","volume":"40","author":"Whited","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.transproceed.2025.05.018_bib0024","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.transproceed.2025.05.018_bib0025","first-page":"2374","article-title":"Hematology: basic principles and practice","author":"Hoffman","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.transproceed.2025.05.018_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.transproceed.2025.05.018_bib0027","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jtct.2021.12.014","article-title":"Risk factors for early cytomegalovirus reactivation and impact of early cytomegalovirus reactivation on clinical outcomes after T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Mariotti","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.transproceed.2025.05.018_bib0028","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000508169","article-title":"Extracorporeal photopheresis in graft-versus-host disease","volume":"47","author":"Drexler","year":"2020","journal-title":"Transfusion Med Hemother"},{"issue":"19","key":"10.1016\/j.transproceed.2025.05.018_bib0029","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2025.05.018_bib0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fimmu.2018.00389","article-title":"Potential beneficial effects of cytomegalovirus infection after transplantation","volume":"9","author":"Litjens","year":"2018","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.transproceed.2025.05.018_bib0031","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.transproceed.2025.05.018_bib0032","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3324\/haematol.2019.223073","article-title":"European Conference on Infections in Leukaemia (ECIL). Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation","volume":"104","author":"Ward","year":"2019","journal-title":"Haematologica"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525002817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525002817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T16:39:34Z","timestamp":1753288774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134525002817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0041134525002817"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.05.018","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomegalovirus Infection Risk Factors in Allogeneic Hematopoietic Stem Cell Transplantation Can Defibrotide Be a Risk Factor?","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}